Asset Details
Do you wish to reserve the book?
Expression of neuropeptide Y is increased in an activated human HSC cell line
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Expression of neuropeptide Y is increased in an activated human HSC cell line
Do you wish to request the book?
Expression of neuropeptide Y is increased in an activated human HSC cell line
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Expression of neuropeptide Y is increased in an activated human HSC cell line
2019
Overview
Neuropeptide Y (NPY) is an abundant neuropeptide in the mammalian central and peripheral nervous systems. Transgenic mice overexpressing NPY in noradrenergic neurons have increased level of hepatic triglycerides, fatty acids and cholesterol, which contributed to the development of hepatosteatosis. However, the roles of NPY in the activation of hepatic stellate cells (HSCs) and the underlying mechanisms remain unclear. This study aimed to investigate the expression and secretion of NPY in human immortalized HSC LX-2 cells and the regulatory function of NPY on the fibrogenic response in LX-2 cells, to explore the potential association between NPY and LX-2 activation. The results showed an increase in the expression and secretion of NPY(1–36) in activated LX-2 cells. Both endogenous and exogenous NPY(1–36) induced the phosphorylation of mTOR, p70S6K, and 4EBP1 and promoted the fibrogenic response via NPY Y1 receptor subtype (NPY1R), as these responses were blocked by either an NPY1R antagonist (BIBP3226) or NPY1R knockdown. Moreover, NPY(1–36) serum levels were increased in patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC) and presented a positive relationship with MELD scores in LC patients. These findings suggest that immortalized HSCs LX-2 have the potential to produce NPY(1–36). High serum levels of NPY(1–36) is correlated with hepatic dysfunction in cirrhotic patients.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 38/35
/ 38/89
/ 82/80
/ Adaptor Proteins, Signal Transducing - genetics
/ Adaptor Proteins, Signal Transducing - metabolism
/ Arginine - analogs & derivatives
/ Cell Cycle Proteins - genetics
/ Cell Cycle Proteins - metabolism
/ Hepatic Stellate Cells - metabolism
/ Hepatic Stellate Cells - pathology
/ Humanities and Social Sciences
/ Humans
/ Receptors, Neuropeptide Y - antagonists & inhibitors
/ Receptors, Neuropeptide Y - genetics
/ Receptors, Neuropeptide Y - metabolism
/ Ribosomal Protein S6 Kinases, 70-kDa - genetics
/ Ribosomal Protein S6 Kinases, 70-kDa - metabolism
/ Rodents
/ Science
/ TOR Serine-Threonine Kinases - genetics
